Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men

New York Acute Hepatitis C Surveillance Network

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Background. Treatment of HIV-infected men during early hepatitis C virus (HCV) infection with interferon results in a higher cure rate with a shorter duration of treatment than during chronic HCV infection. We recently demonstrated that this phenomenon applied to interferon-free treatment as well, curing most participants with short-course sofosbuvir and ribavirin. Due to the significantly higher potency of the ledipasvir/sofosbuvir (LDV/SOF) combination, we hypothesized that we would be more successful in curing early HCV infections using a shorter course of LDV/SOF than that used for treating chronic HCV infections. Methods. We performed a prospective, open-label, consecutive case series study of 8 weeks of LDV/SOF in HIV-infected men with early genotype 1 HCV infection. The primary end point was aviremia at least 12 weeks after completion of treatment. Results. We treated 25 HIV-infected men with early sexually acquired HCV infection with 8 weeks of LDV/SOF, and all 25 (100%) were cured. Twelve (48%) reported sexualized drug use with methamphetamine. Conclusions. Eight weeks of LDV/SOF cured all 25 HIV-infected men with early HCV infection, including those who were actively using drugs. Based on these results, we recommend treatment of newly HCV-infected men during early infection, regardless of drug use, to both take advantage of this 8-week treatment and to decrease further HCV transmission among this group of men.

Original languageEnglish (US)
JournalOpen Forum Infectious Diseases
Volume5
Issue number10
DOIs
StatePublished - Oct 1 2018
Externally publishedYes

Keywords

  • Acute HCV
  • Enhanced treatment responsiveness
  • HIV-infected men who have sex with men (MSM)
  • Sexualized methamphetamine drug use

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men'. Together they form a unique fingerprint.

Cite this